Form 4: Foghorn Therapeutics Director Ian Smith Reports Stock Option Grant

Ian F. Smith, a Director at Foghorn Therapeutics Inc., reported the acquisition of stock options on June 24, 2026, as per SEC Form 4 filing.

Summary

• Director Ian F. Smith of Foghorn Therapeutics Inc. (FHTX) has filed a Form 4 statement detailing a transaction on June 24, 2026.
• The transaction involved the acquisition of 28,000 stock options with an exercise price of $4.08 per share.
• These options are exercisable on June 23, 2036, and vest in full on the first anniversary of the grant date, contingent upon continued service as a director.
• Following this transaction, Mr. Smith beneficially owns 28,000 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard stock option grant to a director, which is a routine event and does not inherently signal positive or negative performance.

Positives

• Director Ian F. Smith has been granted stock options, indicating potential future equity participation and alignment with the company's performance.
• The grant of 28,000 options suggests a commitment to retaining key leadership and incentivizing long-term value creation.

Risks

• The vesting of options is contingent upon continued service, meaning any departure from the board would forfeit these unvested options.
• The exercise price of $4.08 per share implies that the stock price needs to exceed this level for the options to be profitable.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The details pertain to a grant of stock options with a future vesting and exercise schedule.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, serving as a standard incentive to align executive interests with shareholder value and encourage long-term commitment.

Corporate Governance

Stakeholder Impact

• Shareholders: The option grant aligns director incentives with long-term shareholder value, but the actual impact depends on future stock performance.
• Employees: While not directly impacting employees, such grants can be indicative of the company's strategy to retain and incentivize key personnel.
• Management: Ian F. Smith benefits from the potential for future equity gains, contingent on continued service and company performance.

Next Steps

• Ian F. Smith will continue to serve as a director, subject to the terms of his service.
• The stock options will vest on the first anniversary of the grant date.
• The options can be exercised on or after June 23, 2036, up to the expiration date of June 23, 2036.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, Form 4, Stock Options, Director, SEC Filing, Beneficial Ownership, Equity Grant